Evidence map›Paper›PMID 40623060›Full record

ArticlePloS one2025

An in vitro model to study molecular pathogenesis of sarcopenia established by a SASP-dependent human myotube culture.

Kiyo-Aki Ishii, Ryo Hashimoto, Chikako Umeda, Tohru Hosoyama, Ken Watanabe

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kiyo-Aki IshiiDepartment of Musculoskeletal Disease, National Center for Geriatrics and Gerontology (NCGG), Obu, Japan.ORCID https://orcid.org/0000-0001-9846-5575
Ryo HashimotoDepartment of Musculoskeletal Disease, National Center for Geriatrics and Gerontology (NCGG), Obu, Japan.
Chikako UmedaDepartment of Musculoskeletal Disease, National Center for Geriatrics and Gerontology (NCGG), Obu, Japan.
Tohru HosoyamaDepartment of Musculoskeletal Disease, National Center for Geriatrics and Gerontology (NCGG), Obu, Japan.
Ken WatanabeDepartment of Musculoskeletal Disease, National Center for Geriatrics and Gerontology (NCGG), Obu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia is a condition that affects one's activities of daily livingand is rapidly increasing with the ages of the global population. However, the basic molecular mechanisms for prevention and treatment are not fully understood. Although rodent model animals have many valuable aspects for studying sarcopenia, some aspects and mechanisms differ from humans, such as immune response, metabolism, stress response, and myofiber composition. This study established a human cell-based in vitro model to elucidate the molecular mechanism by which SASP from senescence-induced human mesenchymal stem cells led to the narrowing of human myotube diameter, suggesting that this model is useful for studying sarcopenia. Gene expression profiling was performed the molecular mechanisms and devel on the model by RNA sequencing to identify genes whose expression was affected by SASP. Among these, the exposure to SASP upregulated PDK4 expression, and a PDK4 inhibitor, DCA, could increase myotube diameter and reverse SASP-mediated narrowing of the diameter. Pathway analyses suggested that SASP affected energy metabolism by activating OXPHOS and promoting the expression of mitochondrial function-related genes and mitochondrial biosynthesis factors. These results provide insights that contribute to developing new treatments for sarcopenia.

Indexed as

Cellular SenescenceMuscle Fibers, SkeletalSarcopeniaCells, CulturedEnergy MetabolismGene Expression ProfilingHumansMesenchymal Stem CellsModels, BiologicalPyruvate Dehydrogenase Acetyl-Transferring KinasePDK4 protein, humanPyruvate Dehydrogenase Acetyl-Transferring Kinase

Identifiers

PMID40623060
PMCPMC12233260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.